BRPI0618486A2 - uso de células progenitoras multipotentes em adultos - Google Patents

uso de células progenitoras multipotentes em adultos Download PDF

Info

Publication number
BRPI0618486A2
BRPI0618486A2 BRPI0618486-3A BRPI0618486A BRPI0618486A2 BR PI0618486 A2 BRPI0618486 A2 BR PI0618486A2 BR PI0618486 A BRPI0618486 A BR PI0618486A BR PI0618486 A2 BRPI0618486 A2 BR PI0618486A2
Authority
BR
Brazil
Prior art keywords
cells
adults
methods
progenitor cell
immune response
Prior art date
Application number
BRPI0618486-3A
Other languages
English (en)
Inventor
Robert Deans
Hof Wouter Van't
Richard Maziarz
Magdalena Kovacsovics
Philip Streeter
Original Assignee
Athersys Inc
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc, Univ Oregon Health & Science filed Critical Athersys Inc
Publication of BRPI0618486A2 publication Critical patent/BRPI0618486A2/pt
Publication of BRPI0618486B1 publication Critical patent/BRPI0618486B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

USO DE CéLULAS PROGEMTORAS MiULTIPOTENTES EM ADULTOS. Células isoladas são descritas que são células tronco não embrionárias, células germinativas não embrionárias, e células não germinativas. As células podem diferenciar em pelo menos um tipo de célula de cada um de pelo menos duas das linhagens endodérmica, ectodérmica, e mesodérmica. As células não provocam uma resposta imune prejudicial. As células podem modular respostas imunes. Como um exemplo, as células podem suprimir uma resposta imune em um hospedeiro gerado por células, tecidos, e órgãos alogênicos. Métodos são descritos para usar as células, por si só ou de maneira adjuntiva, para tratar indivíduos. Por exemplo, as células podem ser usadas de maneira adjuntiva à imunossupressão em terapia de transplante. Métodos para obter as células e composições para usá-las também são descritos.
BRPI0618486-3A 2005-11-09 2006-11-09 Uso de células progenitoras multipotentes em adultos BRPI0618486B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/269,736 US8147824B2 (en) 1999-08-05 2005-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US11/269,736 2005-11-09
PCT/US2006/043804 WO2007056578A1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0618486A2 true BRPI0618486A2 (pt) 2011-08-30
BRPI0618486B1 BRPI0618486B1 (pt) 2021-11-30

Family

ID=37808258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618486-3A BRPI0618486B1 (pt) 2005-11-09 2006-11-09 Uso de células progenitoras multipotentes em adultos

Country Status (19)

Country Link
US (6) US8147824B2 (pt)
EP (3) EP1951294B1 (pt)
JP (3) JP5399709B2 (pt)
KR (1) KR101423786B1 (pt)
CN (3) CN104095878B (pt)
AU (1) AU2006311418B2 (pt)
BR (1) BRPI0618486B1 (pt)
CA (3) CA3028315C (pt)
DK (2) DK1951294T3 (pt)
ES (2) ES2778424T3 (pt)
HU (1) HUE055956T2 (pt)
IL (5) IL191317A (pt)
LT (1) LT1951294T (pt)
NZ (2) NZ596022A (pt)
PH (2) PH12021551194A1 (pt)
PL (2) PL2684571T3 (pt)
PT (2) PT1951294T (pt)
RU (1) RU2497530C2 (pt)
WO (1) WO2007056578A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP2338983B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
AU2002251935B2 (en) * 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US8192348B2 (en) * 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
CN101370930A (zh) * 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
CA3028321C (en) 2006-01-23 2022-06-21 Athersys, Inc. Mapc treatment of brain injuries and diseases
US20110171182A1 (en) * 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
NZ606814A (en) 2006-10-23 2014-10-31 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
WO2008063675A2 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
CN103356710A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
EP2203176B1 (en) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2743697A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009073594A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
AU2008333972A1 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising HDAC inhibitors and methods of their use in restoring stem cell function and preventing heart failure
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
SG187493A1 (en) 2008-01-18 2013-02-28 Univ Minnesota Stem cell aggregates and methods for making and using
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
SI2331109T1 (sl) 2008-08-22 2013-10-30 Anthrogenesis Corporation Postopki in sestavki za zdravljenje okvar kosti s populacijami placentarnih celic
WO2010059828A1 (en) 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
SG10201404280XA (en) * 2009-07-21 2014-10-30 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
AU2010276264B2 (en) * 2009-07-21 2013-09-19 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
CA2787992A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
DK2568991T6 (en) 2010-05-12 2019-03-18 Abt Holding Co MODULATION OF SPLENOCYTES IN CELL THERAPY
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US8642027B2 (en) 2010-09-01 2014-02-04 Stemnion, Inc. Compositions and methods for modulating ischemic injury
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2012168295A1 (en) * 2011-06-06 2012-12-13 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2012346645B2 (en) * 2011-12-01 2015-08-27 R Bio Co., Ltd. Culture-medium composition for rejuvenating stem cells
JP6388831B2 (ja) 2012-01-13 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 単離ヒト肺前駆細胞およびその使用
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
ES2927175T3 (es) 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
KR102161726B1 (ko) * 2013-04-12 2020-10-06 사베리오 라프란체스카 이식용 장기의 개선
EP2992088B1 (en) * 2013-04-30 2019-08-21 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017127123A1 (en) 2016-01-21 2017-07-27 Abt Holding Company Stem cells for wound healing
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CN110494556B (zh) 2017-04-03 2024-04-30 株式会社钟化 包含间充质系干细胞的细胞群、其制造方法、以及医药组合物
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
JP7526001B2 (ja) 2017-12-28 2024-07-31 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
JP7454379B2 (ja) 2017-12-28 2024-03-22 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN109735611A (zh) * 2018-12-19 2019-05-10 珠海铂华生物工程有限公司 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用
WO2020184350A1 (ja) 2019-03-08 2020-09-17 株式会社カネカ 多能性幹細胞の大量培養
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
EP4426815A1 (en) 2021-11-05 2024-09-11 Healios K.K. Culture-expanded canine progenitor cells and related methods
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN120129527A (zh) * 2022-09-02 2025-06-10 财团法人医药工业技术发展中心 包含间充质干细胞的组合物在缓解骨髓纤维化上的用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
JPH07316051A (ja) 1994-05-23 1995-12-05 Kanegafuchi Chem Ind Co Ltd 免疫抑制剤としてのベルベリン
IN184685B (pt) 1996-02-14 2000-09-23 Nat Inst Immunology
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999003973A1 (en) 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
WO1999047163A2 (en) 1998-03-18 1999-09-23 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
JP2002510655A (ja) 1998-04-03 2002-04-09 オシリス セラピューティクス，インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
JP2002510747A (ja) * 1998-04-08 2002-04-09 メタボリックス，インコーポレイテッド バイオポリマーの分離および精製のための方法
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP1226233B1 (en) 1999-08-05 2011-06-29 ABT Holding Company Multipotent adult stem cells and methods for isolation
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
DE60127291T2 (de) 2000-11-20 2007-12-20 California Institute Of Technology, Pasadena Für den glatten muskel von arterien und den glatten muskel von venen spezifische proteine und deren verwendung
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
WO2003060082A2 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7105037B2 (en) * 2002-10-31 2006-09-12 Advanced Technology Materials, Inc. Semiconductor manufacturing facility utilizing exhaust recirculation
US7807458B2 (en) 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
US8426200B2 (en) * 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
EP1737947B9 (en) 2004-04-21 2012-04-25 Regents Of The University Of Minnesota Mapc generation of lung tissue
WO2006121454A2 (en) 2005-05-05 2006-11-16 Regents Of The University Of Minnesota Use of mapc or progeny therefrom to populate lymphohematopoietic tissues
AU2005331559B2 (en) 2005-05-05 2012-04-19 Regents Of The University Of Minnesota Use of NK cell inhibition to facilitate persistence of engrafted MHC-I negative cells
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
AU2006304274B2 (en) 2005-10-13 2012-08-16 Celularity Inc. Production of oligodendrocytes from placenta-derived stem cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
CA3028321C (en) 2006-01-23 2022-06-21 Athersys, Inc. Mapc treatment of brain injuries and diseases
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CN103356710A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
KR101158473B1 (ko) 2009-01-15 2012-06-20 코아스템(주) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Also Published As

Publication number Publication date
IL276705B (en) 2022-04-01
ES2778424T3 (es) 2020-08-10
AU2006311418A1 (en) 2007-05-18
JP5897514B2 (ja) 2016-03-30
CA3028315A1 (en) 2007-05-18
PL1951294T3 (pl) 2020-08-24
PH12015502169B1 (en) 2022-02-11
IL191317A (en) 2015-03-31
HUE055956T2 (hu) 2022-01-28
CN101336112A (zh) 2008-12-31
JP2016135763A (ja) 2016-07-28
KR20080092336A (ko) 2008-10-15
HK1214166A1 (zh) 2016-07-22
IL276705A (en) 2020-09-30
JP5399709B2 (ja) 2014-01-29
CA3028315C (en) 2023-09-05
CA2628254C (en) 2023-06-20
NZ568546A (en) 2012-06-29
JP6342880B2 (ja) 2018-06-13
WO2007056578A1 (en) 2007-05-18
DK1951294T3 (da) 2020-03-23
IL191317A0 (en) 2008-12-29
EP1951294B1 (en) 2019-12-25
HK1203058A1 (en) 2015-10-16
PH12021551194A1 (en) 2023-04-24
EP2684571B1 (en) 2021-05-26
CN104873540B (zh) 2019-11-15
PT1951294T (pt) 2020-03-31
PH12015502169A1 (en) 2017-04-24
PT2684571T (pt) 2021-08-30
US20120135043A1 (en) 2012-05-31
US8147824B2 (en) 2012-04-03
EP1951294A1 (en) 2008-08-06
ES2884703T3 (es) 2021-12-10
LT1951294T (lt) 2020-04-10
US9808485B2 (en) 2017-11-07
KR101423786B1 (ko) 2014-07-25
CN101336112B (zh) 2015-05-20
CN104095878B (zh) 2020-01-21
JP2009514979A (ja) 2009-04-09
DK2684571T3 (da) 2021-08-30
CN104095878A (zh) 2014-10-15
RU2497530C2 (ru) 2013-11-10
US20210346429A1 (en) 2021-11-11
CN104873540A (zh) 2015-09-02
AU2006311418B2 (en) 2013-03-14
EP3808373A1 (en) 2021-04-21
US11197889B2 (en) 2021-12-14
IL236832A (en) 2017-08-31
IL249572A0 (en) 2017-02-28
US20180055881A1 (en) 2018-03-01
PL2684571T3 (pl) 2022-01-10
US20150118193A1 (en) 2015-04-30
US9962407B2 (en) 2018-05-08
NZ596022A (en) 2013-06-28
RU2008122943A (ru) 2009-12-20
IL289024A (en) 2022-02-01
IL249572B (en) 2020-08-31
BRPI0618486B1 (pt) 2021-11-30
EP2684571A1 (en) 2014-01-15
JP2013256510A (ja) 2013-12-26
US20060263337A1 (en) 2006-11-23
CA2628254A1 (en) 2007-05-18
CA3206592A1 (en) 2007-05-18
US20090104163A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
PH12015502169B1 (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
BR112023014980A2 (pt) Lentivírus para gerar células que expressam o receptor de antígeno quimérico anti-cd19
PT1226233E (pt) Células estaminais adultas multipotentes e métodos para isolamento
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
BR112018076263A2 (pt) composições e métodos para a depleção de células
PE20200484A1 (es) Tratamiento para el asma con anticuerpo anti-tslp
BR112021021608A2 (pt) Células car-t direcionadas a cd19 específicas para antígeno
GB2432166B (en) Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
Hashemi et al. Comparative immunomodulatory properties of adipose‐derived mesenchymal stem cells conditioned media from BALB/c, C57BL/6, and DBA mouse strains
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
MY159971A (en) Multipotent/pluripotent cells and methods
PE20110020A1 (es) Inmunomodulacion mediante el uso de celulas madres de la placenta
BR112013003823A2 (pt) conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
BR112018072701A2 (pt) métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
AR054180A1 (es) Metodos y aparatos para la reduccion del contenido de proteina en extendedores de celulas de esperma
WO2006047743A3 (en) Swine multipotent adult progenitor cells
WO2017015245A8 (en) Methods and compositions for stem cell transplantation
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
CO2021012294A2 (es) Composiciones de lawsonia intracellularis y métodos de uso de las mismas
MX2024001208A (es) Celulas primarias geneticamente modificadas para terapia celular alogenica.
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
BR112021021349A2 (pt) Métodos de fabricação de células car t alogênicas
IN2012DN05181A (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: OREGON HEALTH AND SCIENCE UNIVERSITY (US) ; ABT HO

Owner name: OREGON HEALTH AND SCIENCE UNIVERSITY (US) ; ABT HOLDING COMPANY (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2853 DE 09-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.